Strategies and challenges for the next generation of antibody –drug conjugates

Nature Reviews Drug Discovery 16, 315 (2017). doi:10.1038/nrd.2016.268 Authors: Alain Beck, Liliane Goetsch, Charles Dumontet & Nathalie Corvaïa Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that are evaluating more than 60
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research